查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1356890

囊性纤维化市场报告：2030 年趋势、预测与竞争分析

Cystic Fibrosis Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

囊性纤维化趋势与预测

到 2030 年，全球囊性纤维化市场预计将达到 109 亿美元，2024 年至 2030 年年复合成长率为 8.6%。这个市场的主要驱动因素是基因组变异病例数量的增加、患者对口服疗法的偏好增加以及管道患者数量的增加。全球囊性纤维化市场的未来性充满希望，零售药局/药局、线上药局和医院药局市场充满机会。

囊性纤维化市场洞察

Lucintel预测，由于旨在改善细胞体功能、改善患者生活品质、减少肺炎和呼吸道症状的扩大应用，囊性纤维化跨膜电导控制药物将在预测期内出现最高增长率。

预计线上药局在预测期内将出现最高成长。

由于患有各种呼吸道疾病的患者数量不断增加、医疗基础设施的持续进步以及关键参与者的存在，预计北美在预测期内将出现最高的增长。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球囊性纤维化市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球囊性纤维化市场趋势（2018-2023）与预测（2024-2030）
  • 按药物类别分類的全球囊性纤维化市场
    • 囊性纤维化跨膜电导调节因子
    • 支气管扩张剂
    • 黏液溶解剂
    • 胰酵素补充剂
    • 其他的
  • 按给药途径的全球囊性纤维化市场
    • 口服
    • 胃肠外的
  • 全球囊性纤维化市场（依最终用途）
    • 零售药局和药局
    • 网路药房
    • 医院药房
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球囊性纤维化市场（按地区）
  • 北美洲囊性纤维化市场
  • 欧洲囊性纤维化市场
  • 亚太地区囊性纤维化市场
  • 其他区域囊性纤维化市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按药物类别分類的全球囊性纤维化市场成长机会
    • 按给药途径分類的全球囊性纤维化市场成长机会
    • 全球囊性纤维化市场成长机会（依最终用途）
    • 全球囊性纤维化市场成长机会（按地区）
  • 全球囊性纤维化市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 全球囊性纤维化市场容量扩张
    • 全球囊性纤维化市场的合併、收购与合资企业
    • 认证和许可

第7章主要企业概况

  • Gilead Sciences
  • Vertex Pharmaceuticals
  • Novartis
  • Allergan
  • AbbVie
  • Teva Pharmaceutical Industries
  • F. Hoffmann-La Roche
  • Pharmaxis
  • Mylan
  • GlaxoSmithKline
简介目录

Cystic Fibrosis Trends and Forecast

The future of the global cystic fibrosis market looks promising with opportunities in the retail pharmacy & drug store, online pharmacy, and hospital pharmacy markets. The global cystic fibrosis market is expected to reach an estimated $10.9 billion by 2030 with a CAGR of 8.6% from 2024 to 2030. The major drivers for this market are growing cases of genomic mutations, rising patients preference for oral treatment, and augmenting number of pipeline patients.

A more than 150-page report is developed to help in your business decisions.

Cystic Fibrosis by Segment

The study includes a forecast for the global cystic fibrosis by drug class, route of administration, end use, and region.

Cystic Fibrosis Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
  • Bronchodilators
  • Mucolytic
  • Pancreatic Enzyme Supplement
  • Others

Cystic Fibrosis Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Oral
  • Parenteral

Cystic Fibrosis Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Retail Pharmacies & Drug Stores
  • Online Pharmacies
  • Hospital Pharmacies
  • Others

Cystic Fibrosis Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cystic Fibrosis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cystic fibrosis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cystic fibrosis companies profiled in this report include-

  • Gilead Sciences
  • Vertex Pharmaceuticals
  • Novartis
  • Allergan
  • Abbvie
  • Teva Pharmaceutical Industries
  • F. Hoffmann-La Roche
  • Pharmaxis
  • Mylan
  • Glaxosmithkline

Cystic Fibrosis Market Insights

Lucintel forecasts that cystic fibrosis transmembrane conductance regulator is expected to witness highest growth over the forecast period due to its expanding use to improve cellular body function, enhance patients' quality of life, and lessen lung flare-ups and respiratory symptoms.

Online pharmacy is expected to witness highest growth over the forecast period.

North America is expected to witness highest growth over the forecast period due to increasing number of people with various respiratory diseases, continous healthcare infrastructural advancement, and presence of key players in the region.

Features of the Global Cystic Fibrosis Market

Market Size Estimates: Cystic fibrosis market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cystic fibrosis market size by various segments, such as by route of administration, end use, and region. in terms of value ($B).

Regional Analysis: Cystic fibrosis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different route of administrations, end uses, and region.s for the cystic fibrosis market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cystic fibrosis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the cystic fibrosis market size?

Answer: The global cystic fibrosis market is expected to reach an estimated $10.9 billion by 2030.

Q.2. What is the growth forecast for cystic fibrosis market?

Answer: The global cystic fibrosis market is expected to grow with a CAGR of 8.6% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the cystic fibrosis market?

Answer: The major drivers for this market are growing cases of genomic mutations, rising patients preference for oral treatment, and augmenting number of pipeline patients.

Q.4. What are the major segments for cystic fibrosis market?

Answer: The future of the cystic fibrosis market looks promising with opportunities in the retail pharmacy & drug store, online pharmacy, and hospital pharmacy markets.

Q.5. Who are the key cystic fibrosis market companies?

Answer: Some of the key cystic fibrosis companies are as follows:

  • Gilead Sciences
  • Vertex Pharmaceuticals
  • Novartis
  • Allergan
  • AbbVie
  • Teva Pharmaceutical Industries
  • F. Hoffmann-La Roche
  • Pharmaxis
  • Mylan
  • GlaxoSmithKline

Q.6. Which cystic fibrosis market segment will be the largest in future?

Answer: Lucintel forecasts that cystic fibrosis transmembrane conductance regulator is expected to witness highest growth over the forecast period due to its expanding use to improve cellular body function, enhance patients' quality of life, and lessen lung flare-ups and respiratory symptoms.

Q.7. In cystic fibrosis market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to increasing number of people with various respiratory diseases, continous healthcare infrastructural advancement, and presence of key players in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cystic fibrosis market by drug class (cystic fibrosis transmembrane conductance regulator (CFTR), bronchodilators, mucolytic, pancreatic enzyme supplement, and others), route of administration (oral and parenteral), end use (retail pharmacies & drug stores, online pharmacies, hospital pharmacies, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cystic Fibrosis Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cystic Fibrosis Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cystic Fibrosis Market by Drug Class
    • 3.3.1: Cystic Fibrosis Transmembrane Conductance Regulator
    • 3.3.2: Bronchodilators
    • 3.3.3: Mucolytic
    • 3.3.4: Pancreatic Enzyme Supplement
    • 3.3.5: Others
  • 3.4: Global Cystic Fibrosis Market by Route of Administration
    • 3.4.1: Oral
    • 3.4.2: Parenteral
  • 3.5: Global Cystic Fibrosis Market by End Use
    • 3.5.1: Retail Pharmacies & Drug Stores
    • 3.5.2: Online Pharmacies
    • 3.5.3: Hospital Pharmacies
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cystic Fibrosis Market by Region
  • 4.2: North American Cystic Fibrosis Market
    • 4.2.2: North American Cystic Fibrosis Market by End Use: Retail Pharmacies & Drug Stores, Online Pharmacies, Hospital Pharmacies, and Others
  • 4.3: European Cystic Fibrosis Market
    • 4.3.1: European Cystic Fibrosis Market by Drug Class: Cystic Fibrosis Transmembrane Conductance Regulator, Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement, and Others
    • 4.3.2: European Cystic Fibrosis Market by End Use: Retail Pharmacies & Drug Stores, Online Pharmacies, Hospital Pharmacies, and Others
  • 4.4: APAC Cystic Fibrosis Market
    • 4.4.1: APAC Cystic Fibrosis Market by Drug Class: Cystic Fibrosis Transmembrane Conductance Regulator, Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement, and Others
    • 4.4.2: APAC Cystic Fibrosis Market by End Use: Retail Pharmacies & Drug Stores, Online Pharmacies, Hospital Pharmacies, and Others
  • 4.5: ROW Cystic Fibrosis Market
    • 4.5.1: ROW Cystic Fibrosis Market by Drug Class: Cystic Fibrosis Transmembrane Conductance Regulator, Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement, and Others
    • 4.5.2: ROW Cystic Fibrosis Market by End Use: Retail Pharmacies & Drug Stores, Online Pharmacies, Hospital Pharmacies, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cystic Fibrosis Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Cystic Fibrosis Market by Route of Administration
    • 6.1.3: Growth Opportunities for the Global Cystic Fibrosis Market by End Use
    • 6.1.4: Growth Opportunities for the Global Cystic Fibrosis Market by Region
  • 6.2: Emerging Trends in the Global Cystic Fibrosis Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cystic Fibrosis Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cystic Fibrosis Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Gilead Sciences
  • 7.2: Vertex Pharmaceuticals
  • 7.3: Novartis
  • 7.4: Allergan
  • 7.5: AbbVie
  • 7.6: Teva Pharmaceutical Industries
  • 7.7: F. Hoffmann-La Roche
  • 7.8: Pharmaxis
  • 7.9: Mylan
  • 7.10: GlaxoSmithKline